Cencora Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale CGT Programs
核心洞察
Cencora launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions (搜索) portfolio on September 2, 2026, to help health systems evaluate, build, and scale cell and gene therapy programs.
Only 4% of health system pharmacy leaders report being fully prepared to integrate cell and gene therapies, despite more than 35 FDA approvals and over 1,700 clinical trials underway globally.
The offering provides tailored support across three pillars: financial confidence, operational readiness, and scalable growth, spanning market assessment, governance design, and workflow planning.
Cencora, Inc. has unveiled a new service designed to help health systems evaluate, build, and scale cell and gene therapy (CGT) programs. Announced on September 2, 2026, the offering — Cell and Gene Therapy Enablement — is delivered through Accelerate Pharmacy Solutions (搜索) (APS), Cencora's integrated portfolio of pharmacy and supply chain solutions. The initiative aims to strengthen operational readiness and program execution to reduce barriers to care and expand patient access to advanced therapies.
"Cell and gene therapies have the potential to transform care for patients with serious and complex diseases, but delivering them requires coordinated execution across strategy, finance, clinical operations, pharmacy and patient access," said Ryan Telford, Vice President, Health System Pharmacy Portfolio Strategy at Accelerate Pharmacy Solutions (搜索), Cencora.
A Structural Gap in Readiness
The launch responds to a significant disconnect between the growth of the CGT field and health systems' capacity to deliver these therapies. More than 35 cell and gene therapies have been approved by the U.S. Food and Drug Administration (FDA), and more than 1,700 clinical trials are underway globally, including products targeting indications with larger patient populations. Yet only 4% of health system pharmacy leaders surveyed in a recent report said their organizations were fully prepared to integrate these therapies.
This gap underscores the need for stronger infrastructure, resource allocation, and operational alignment to alleviate barriers to care. Louis Cicchini, Senior Director, Scientific Affairs and Strategic Partnerships, CGT Service Line at Cencora, framed the challenge as a structural issue for the industry: "Fulfilling the clinical promise of these therapies is heavily dependent on health systems strategically expanding their capabilities. As an industry, we have to collaborate across silos to sustainably deliver advanced therapies and make accessing that care easier for patients."
Three Pillars of Support
The Cell and Gene Therapy Enablement team will provide health systems with tailored support across three key areas:
Financial confidence encompasses CGT market assessment, including therapy-specific financial considerations, reimbursement dynamics, and site-of-care considerations.
Operational readiness supports program launch or expansion through readiness assessments, gap analysis, strategic roadmap development, governance design, and workflow planning.
Scalable growth focuses on establishing repeatable operating models to drive coordinated execution across strategy, finance, clinical operations, pharmacy, and patient access teams, supporting expansion across therapies, sites, and indications.
Telford described the approach as building "on our existing capabilities to provide health systems with tailored support – from market landscape and readiness assessments to governance design, implementation and optimization – to help them launch or expand their CGT programs."
Cencora's Broader CGT Footprint
As a leader in specialty pharmaceutical services, Cencora provides integrated CGT solutions across the product lifecycle, including commercialization support to help developers bring products to market, as well as specialty distribution and provider solutions to support reliable, efficient access across sites of care. Combined with Accelerate Pharmacy Solutions (搜索)' patient delivery expertise, this offering expands Cencora's CGT capabilities and strengthens the support the company provides to healthcare providers to reduce barriers and improve access.
"Investing in solutions to support and elevate the care model is a win for patients, providers and developers," Cicchini added.
Cencora is a global pharmaceutical solutions organization focused on improving the lives of people and animals, partnering with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. The company employs more than 51,000 team members worldwide and is ranked #10 on the Fortune 500 and #16 on the Global Fortune 500, with more than $300 billion in annual revenue. The announcement did not name specific health system partners already using the service or specify when broader availability begins.